News & Analysis on Clinical Trial Services & Contract Research And Development
Scientists have successfully achieved the production of a functional humanised antibody in the whites of eggs laid by a transgenic hen, opening the door to using transgenic flocks as an alternative to mammalian cell culture for the production of many...
US company Nabi Biopharmaceuticals has officially opened its new vaccine manufacturing facility in Boca Raton, Florida.
Dynal Biotech has announced two product releases from its new proteomic preparation range, which use magnetic bead chromatography technology to prepare for mass spectrum analysis without the requirement of columns.
In-PharmaTechnologist.com reports its periodic round-up of new appointments in the pharmaceutical sector, headlined this week by the appointment of a new head of manufacturing at US drugmaker Merck & Co.
One of the biggest challenges in catalysed chemical reactions is to remove and recycle the catalyst once the process is complete. A new approach, using Teflon, could make recovery simpler and cut down on the use of solvents, writes Phil Taylor.
The European pharmaceutical sector is falling behind the US in terms of innovation and R&D expenditure and is increasingly under threat from newcomers, especially in India and China.
Security printing specialist AlpVision has signed an agreement with fellow Swiss company Serolab to develop packaging that will guard against drug counterfeiting.
Researchers have identified the first gene in patients who have epilepsy, which is associated with a movement disorder. The study provides the first direct genetic evidence that the co-existence of these conditions represents a new syndrome.
Nanostream, has introduced a fraction collector add-on to its Veloce system, transforming it into a front-end sample preparation tool that lets users rapidly perform MS assays.
Researchers have come up with a unique method of detecting cancer in which gold nanoparticles that were bound to a specific antibody displayed a 600 per cent greater affinity for cancer cells than for noncancerous cells.
French plant extracts supplier Naturex said today it will buy US rival Pure World for around $37 million (€30m), or $4.30 per share in cash, reports Dominique Patton.